-
公开(公告)号：US06902728B1
公开(公告)日：2005-06-07
申请号：US09787335
申请日：1999-09-16
CPC分类号： C07K14/521 , Y10S514/885
摘要： The use of a chemokine receptor antagonist together with a cyclosporin to produce a pharmaceutical composition for treating or preventing rejection of transplanted organs, tissues or cells is herein disclosed. Said pharmaceutical compositions for the simultaneous, sepatate or sequential use of its active ingredients for the above specified therapy are also disclosed and claimed. In particular, the use of Met-RANTES together with cyclosporin A to produce a pharmaceutical composition for the treatment of renal allograft transplant rejection is experimentally shown.
摘要翻译： 本文公开了将趋化因子受体拮抗剂与环孢菌素一起用于产生用于治疗或预防移植器官，组织或细胞排斥的药物组合物。 用于同时，分离或顺序使用其用于上述指定治疗的活性成分的所述药物组合物也被公开和要求保护。 特别地，实验上显示使用Met-RANTES与环孢菌素A一起制备用于治疗肾同种异体移植排斥的药物组合物。
-
公开(公告)号：US20160136207A1
公开(公告)日：2016-05-19
申请号：US14707739
申请日：2015-05-08
IPC分类号： A61K35/545 , A61K38/18
CPC分类号： A61K35/545 , A61K35/12 , A61K35/28 , A61K38/1709 , A61K38/18 , A61K38/1866 , A61K48/00 , A61K2035/122 , A61K2035/124 , C07K14/49 , C12N5/0663
摘要： This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34 stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34 stem cells used in the instant methods can be genetically, modified or not, depending on the disorder treated.
-
公开(公告)号：USD251309S
公开(公告)日：1979-03-13
申请号：US718030
申请日：1976-08-26
申请人： Peter J. Nelson
设计人： Peter J. Nelson
-
公开(公告)号：US06448039B1
公开(公告)日：2002-09-10
申请号：US09341007
申请日：1999-06-30
IPC分类号： C07H2104
CPC分类号： C07K14/4702 , C07K14/4705 , C07K14/523 , C12N15/67 , C12N15/85 , C12N2830/00 , C12N2830/30 , C12N2830/85
摘要： The present invention provides elements derived from a human RANTES promoter that induce expression of a heterologous coding sequence. The invention further provides expression vectors comprising the elements, and host cells comprising the expression vectors. The invention further provides methods of inducing the expression of a heterologous protein in a host.
摘要翻译： 本发明提供衍生自诱导异源编码序列表达的人RANTES启动子的元件。 本发明还提供了包含这些元件的表达载体和包含表达载体的宿主细胞。 本发明进一步提供诱导异源蛋白在宿主中表达的方法。
-
5.发明授权Tissue inhibitor of metalloproteinases (TIMP) linked to glycosylphosphatidylinositol (GPI)-anchors for treatment of cancer and skin lesions 有权与糖基磷脂酰肌醇（GPI）连接的金属蛋白酶组织抑制剂（TIMP）用于治疗癌症和皮肤病变公开(公告)号：US09255139B2
公开(公告)日：2016-02-09
申请号：US11992213
申请日：2006-09-20
申请人： Ralf Huss , Peter J. Nelson
发明人： Ralf Huss , Peter J. Nelson
CPC分类号： A61K38/57 , A61K38/1709 , A61K47/544 , A61K47/549 , A61K47/62 , C07K14/8146
摘要： The present invention relates to fusion constructs of glycosylphosphatidylinositol (GPI)-anchored tissue inhibitors of metalloproteinases (TIMPs) and their use for the treatment of cancer and in regenerative medicine. By this approach, the GPI-anchored TIMP proteins are incorporated into the surface membrane of tumor cells and render tumor cells sensitive to FAS-induced apoptosis. Furthermore, the fusion constructs of the present invention are effective agents useful in wound healing applications. In one embodiment, the TIMP is linked to mucin followed by GPI in order to enhance surface presentation. The use of GPI to link TIMP renders the resulting fusion protein particularly useful as an anti-cancer agent for the treatment of cancer, and, in particular, any residual cancer following an incomplete surgical resection of primary tumors in an individual.
摘要翻译： 本发明涉及糖基磷脂酰肌醇（GPI） - 金属蛋白酶组织抑制剂（TIMP）的融合构建体及其在再生医学中的应用。 通过这种方法，GPI锚定的TIMP蛋白被并入肿瘤细胞的表面膜，并使肿瘤细胞对FAS诱导的细胞凋亡敏感。 此外，本发明的融合构建体是可用于伤口愈合应用的有效试剂。 在一个实施方案中，TIMP与粘蛋白连接，然后与GPI连接，以增强表面表达。 使用GPI连接TIMP使所得到的融合蛋白特别可用作治疗癌症的抗癌剂，特别是在个体不完全手术切除原发性肿瘤后的任何残留癌症。
-
-
-
-
搜索结果
5 条记录 (耗时 0.022 秒)